Searchable abstracts of presentations at key conferences in endocrinology

ea0090p444 | Reproductive and Developmental Endocrinology | ECE2023

Gender Affirming Hormonal Treatment (GAHT) and Demographics of Slovenian Transgender Adults

Mlekus Kozamernik Katarina , Krokter Kogoj Tina

Introduction: The number of individuals seeking gender-affirming hormonal treatment (GAHT), as well as the ratio between transgender men and transgender women, has increased over the past two decades. The type of GAHT varies significantly among different countries due to differences in availability and reimbursement policies. We aimed to analyze the kinds of GAHT and demographic characteristics of transgender adults at our endocrine clinic, the only center caring for transgend...

ea0081ep208 | Calcium and Bone | ECE2022

Patient with mediastinal mass and hypercalcemia

Mlekus Kozamernik Katarina , Salobir Barbara , Hočevar Marko , Kocjan Tomaž

Introduction: Hypercalcemia is mostly caused by primary hyperparathyroidism and malignancy. Parathyromatosis is a rare condition characterized by multiple nodules of hyperfunctioning parathyroid tissue scattered throughout the neck and superior mediastinum, which can present a diagnostic and therapeutic challenge.Case report: A 56-year-old woman visited the ER due to chest pain, left-sided neck edema, and hematoma. The day before, she experienced left-si...

ea0090p583 | Calcium and Bone | ECE2023

Impact of Zoledronate or Denosumab on Bone-related Biochemical Parameters in Osteoporotic Postmenopausal Women with Primary Hyperparathyroidism

Mlekus Kozamernik Katarina , Ležaić Luka , Hočevar Marko , Kocjan Tomaž

Introduction: Antiresorptive treatment can preserve bone mineral density (BMD) in patients with primary hyperparathyroidism (PHPT) when surgery is not feasible or desired. We aimed to compare the impact of zoledronate vs denosumab on bone-related biochemical parameters in this population.Methods: We analyzed preliminary data from our ongoing randomized trial on osteoporotic postmenopausal women with PHPT who are being treated either with zoledronate 5 mg...